Phase 2 N=1 Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
Ameloblastoma · BRAF Gene Mutation
Primary: Tumor Response — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=2 A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors
Keratocystic Odontogenic Tumor
Primary: KCOT Volume (Greatest Dimension) — 3; 3.8; 0; 2.6 centimeter
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
N/A N=22 Bone Augmentation Techniques in Extraction Sockets
Tooth Loss
Primary: Changes in Hard Tissue Composition — 35.82; 31.76 mm
N/A N=93 Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia
Oral Epithelial Dysplasia, Mild or Moderate Grade
Primary: The Number of Participants With Both Clinical and Histological Evidence of Malignant Transformation of Oral Epithelial Dysplasia — 32; 46 participants
Phase 2 N=17 Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
Desmoid Tumors · Aggressive Fibromatosis
Primary: Number of Participants With a Complete Response (CR) + Partial Response (PR) — 0; 5; 1; 11 Participants
Phase 4 N=41 EMD and/or Bone Substitute for the Treatment of Class II Furcations
Periodontal Disease
Primary: Relative Horizontal Clinical Attachment Level (RHCAL) at 12 Months — 2.31; 3.00; 2.57 mm
Phase 3 N=87 Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Desmoid Fibromatosis
Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001
Phase 2 N=1 Vismodegib for Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Mohs Micrographic Surgery (MMS) — 1 mm
N/A N=62 Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Phase 2 N=28 Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Basal Cell Carcinoma
Primary: Efficacy of Vismodegib — 2; 5; 1; 1 tumors
Phase 2 N=20 GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Neoplasms, Oral · Mouth Neoplasms
Primary: Number of Participants With Changes in Putative Tumor Initiating Cell Populations as Defined by Cell Surface CD44 and Intracellular Phospho-ERK1/2 Staining After…
Phase 2 N=72 PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Phase 2 N=31 Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
Adult Medulloblastoma
Primary: Objective Response (CR+PR) Sustained for ≥ 8 Weeks — 0; 0.15; 0 proportion of participants
N/A N=19 Clinical and Histological Outcomes of Allogenic Amnion Chorion Membrane in the Healing of Free Gingival Graft Donor Site
Palatal Wound
Primary: Size of Wound Area — 80; 80 micrometers (μm)
Phase 2 N=55 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Malignant Salivary Gland Neoplasm · Recurrent Salivary Gland Carcinoma · Salivary Gland Adenoid Cystic Carcinoma
Primary: Response Rate — 0; 0; 1; 0 participants
Phase 2 N=33 Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
Primary: Overall Response Rate — 0; 3; 25; 4 Participants
Phase 2 N=1,215 STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse…
Phase 2 N=34 Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Metastatic Adenoid Cystic Carcinoma · Progressive Disease · Recurrent Adenoid Cystic Carcinoma
Primary: Assess the Objective Response Rate (ORR) to Axitinib and Avelumab Combination According to RECIST 1.1 Criteria. — 18 percentage of participants
Phase 2 N=11 An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
Tenosynovial Giant Cell Tumor · Pigmented Villonodular Synovitis (PVNS)
Primary: Number of Participants With Treatment-emergent Adverse Events — 7; 2 Participants
Phase 2 N=24 Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Locally Advanced Basal Cell Carcinoma · Skin Cancer · Cutaneous Malignancy
Primary: Percentage of Patients With Local-regional Control Rate — 100 percentage
Phase 2 N=18 Cell Therapy for Craniofacial Bone Defects
Cleft Palate · Trauma
Primary: Bone Regeneration — 1.5; 3.3 implant sites
Phase 2 N=9 Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Thyroid Cancer · Anaplastic Thyroid Cancer · Undifferentiated Thyroid Cancer
Primary: Number of Participants With Overall Response (OR) — 0 Participants
N/A N=66 Histological Evaluation of Healing Following Ridge Preservation Using a Combined Cortical/Cancellous Mineralized Freeze-Dried Bone Allograft
Alveolar Bone Loss
Primary: % Vital Bone Formation (Histological) — 26.4; 24.5; 28.8 percentage of total area
N/A N=4 Amnion-Chorion Allograft Barrier Used for Root Surface and Guided Tissue Regeneration
Periodontal Diseases
Primary: Probing Depth Change — 4.22 millimeter
Phase 2 N=41 Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Squamous Cell Carcinoma of Mouth · Intraepithelial Neoplasia
Primary: Light Microscopic Histologically Scored Diagnoses Pretreatment to Post Treatment — 2.36; 2.83; 1.9; 2.58 unit on histologic grade scale — p=0.048
Phase 2 N=24 Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy
Alveolar Bone Loss
Primary: Bone Regeneration — 79; 63 % bone height
Phase 2 N=74 A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Complete Histologic Clearance — 42.0; 16.0; 44.0 Percentage of participants — p=0.8463
N/A N=9 Bioactive Glass (Sol-gel) for Alveolar Bone Regeneration After Surgical Extraction
Bone Loss · Vertical Alveolar Bone Loss · Horizontal Alveolar Bone Loss
Primary: Change in Alveolar Crestal Bone Height — 0.32; 0.84; 1.59; 0.96 mm
N/A N=15 The Horizontal Ridge Augmentation Using Equine Xenograft and a Collagenated Porcine Cortical Lamina
Horizontal Ridge Deficiency
Primary: Change From Baseline in Radiological Bone Width Augmentation at 0 mm — 2.274 mm